Antisense and RNAi Therapeutics Market Size Report, 2032

Antisense and RNAi Therapeutics Market – Technology (RNA Interference, Antisense RNA), Route of Administration (Intrathecal, Intravenous, Subcutaneous), Application (Neurodegenerative, Cancer, Skin, Genetic Disorders) – Global Forecast (2024 – 2032)

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Increasing prevalence of neurodegenerative and genetic disorders

3.2.1.2&nbsp;&nbsp;&nbsp;Growing investments in research related to gene expression and delivery technologies

3.2.1.3&nbsp;&nbsp;&nbsp;Growth in regulatory approvals for RNAi and antisense therapeutics

3.2.1.4&nbsp;&nbsp;&nbsp;Rising awareness towards RNA-based therapeutics

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;Requirement for significant investments in clinical studies

3.2.2.2&nbsp;&nbsp;&nbsp;High cost of RNA-based therapies

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.6&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.3&nbsp;&nbsp;&nbsp; Company matrix analysis

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Technology, 2021 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; RNA interference

5.3&nbsp;&nbsp;&nbsp; Antisense RNA

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Route of administration, 2021 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Intravenous injections

6.3&nbsp;&nbsp;&nbsp; Intrathecal injections

6.4&nbsp;&nbsp;&nbsp; Subcutaneous injections

6.5&nbsp;&nbsp;&nbsp; Other routes of administration

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Application, 2021 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Cardiometabolic &amp; renal disorders

7.3&nbsp;&nbsp;&nbsp; Cancer

7.4&nbsp;&nbsp;&nbsp; Neurodegenerative disorders

7.5&nbsp;&nbsp;&nbsp; Genetic disorders

7.6&nbsp;&nbsp;&nbsp; Infectious diseases

7.7&nbsp;&nbsp;&nbsp; Ophthalmic diseases

7.8&nbsp;&nbsp;&nbsp; Skin diseases

7.9&nbsp;&nbsp;&nbsp; Other applications

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Netherlands

8.3.7&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; China

8.4.2&nbsp;&nbsp;&nbsp; Japan

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp; Middle East and Africa

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; UAE

8.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; Alnylam Pharmaceuticals, Inc.

9.2&nbsp;&nbsp;&nbsp; Arbutus Biopharma

9.3&nbsp;&nbsp;&nbsp; Arrowhead Pharmaceuticals, Inc.

9.4&nbsp;&nbsp;&nbsp; Benitec Biopharma Inc.

9.5&nbsp;&nbsp;&nbsp; BioNTech SE.

9.6&nbsp;&nbsp;&nbsp; CRISPR Therapeutics

9.7&nbsp;&nbsp;&nbsp; GlaxoSmithKline plc

9.8&nbsp;&nbsp;&nbsp; Ionis Pharmaceuticals, Inc.

9.9&nbsp;&nbsp;&nbsp; Novartis AG

9.10&nbsp;&nbsp;&nbsp; OliX Pharmaceuticals, Inc.

9.11&nbsp;&nbsp;&nbsp; Orna Therapeutics, Inc.

9.12&nbsp;&nbsp;&nbsp; Percheron Therapeutics Ltd.

9.13&nbsp;&nbsp;&nbsp; Sanofi

9.14&nbsp;&nbsp;&nbsp; Sarepta Therapeutics, Inc.

9.15&nbsp;&nbsp;&nbsp; Silence Therapeutics 
&nbsp;

Antisense and RNAi Therapeutics Market

Get a free sample of this report